LATEST TRIALS

  • Head And Neck Cancer
    Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (MK1454-002)
  • Lung Cancer
    Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma (NIPU)
  • Cholangiocarcinoma
    A Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Cholangiocarcinoma

NORDIC COOPERATION

Norway Norway Sweden Finland Finland Finland Aarhus Herlev Copenhagen Copenhagen Lund